The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 332:1509-1511 June 1, 1995 Number 22
NextNext

Interferon and Hepatitis C

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
An estimated 3.5 million people in the United States have chronic hepatitis C. Each year, 8000 to 10,000 chronically infected patients die of liver-related complications, and 1000 undergo liver transplantation1 (and Alter M: personal communication). Interferon alfa is the only drug approved for the treatment of hepatitis C in Europe and North America. In the short term, about 50 percent of patients have a response to interferon, but the long-term results have been disappointing.2 After the completion of standard therapy (3 million units three times weekly for six months), 25 percent of patients or less have a sustained biochemical remission, . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.